Introduction
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, and afatinib are effective treatments for EGFR mutant non-small cell lung cancers (NSCLCs) (1) (2) (3) (4) (5) . Although most patients with EGFR mutant NSCLC respond to these therapies, the responses are not permanent, and patients typically develop resistance after an average of one year on treatment (6) . There are several mechanisms of acquired resistance to erlotinib, including the development of a "gatekeeper" point mutation, T790M, which prevents the TKI from effectively inhibiting EGFR (7, 8) , reactivation of downstream signaling pathways via bypass tracks (9) (10) (11) (12) (13) (14) , and phenotypic/histological changes such as Epithelial to Mesenchymal Transition (EMT) or Small Cell Lung Cancer (SCLC ) transformation (12, 14, 15) .
T790M is the most common resistance mechanism in these cancers and is observed in over 50% of resistant biopsies (12, 14) .
Second generation EGFR inhibitors, including afatinib (BIBW2992) and dacomitinib (PF00299804), are irreversible EGFR inhibitors that bind to Cys797 and have been shown in preclinical experiments to effectively inhibit EGFR with activating mutations (Exon 19 deletion or L858R) as well as those with the T790M resistance mutation (16, 17) . However, their activity in patients with erlotinib-resistant cancers harboring T790M has been minimal (18, 19) . The discordance between laboratory and clinical results is likely due to a poor therapeutic window.
These drugs are equally potent against wild type EGFR and EGFR T790M, and thus the toxicity resulting from inhibiting wild type EGFR (rash and diarrhea) precludes the use of doses that would be needed to effectively suppress T790M (20) . More recently, third generation EGFR TKIs including WZ4002, CO-1686, AZD9291 and EGF816 have been developed to target mutant EGFR harboring T790M (21) (22) (23) (24) . This class of inhibitor also binds covalently to Cys797, and largely spares WT EGFR, thereby decreasing toxicity and permitting the use of doses that fully suppress T790M. This large therapeutic window likely underlies the greater than 50% response rates observed in clinical trials with CO-1686 and AZD-9291 in erlotinib-resistant, T790M-positive NSCLCs (25, 26) . Based on these promising results, both drugs have received FDA, "breakthrough therapy designation" and this class of inhibitors is on the verge of becoming widely implemented for treatment of this patient population. Previous studies have generated acquired resistance to third generation inhibitors in well-studied cell lines, and have identified mechanisms that have also been observed in cancers with acquired resistance to first generation EGFR inhibitors. These include EMT (22) , sustained activation of the MAPK kinase pathway (27) , and IGF1R bypass signaling as resistance mechanisms (28) . Herein, we utilize T790M positive cells derived from a biopsy of an erlotinib-resistant tumor to cultivate resistance to a third generation EGFR TKI. In doing so, we identify a widely anticipated resistance mechanism specific to third generation EGFR inhibitors, a C797S resistance mutation, that prevents this class of drugs from effectively suppressing EGFR activity. We also determine that the presence of T790M, whether in cis or trans to C797S, markedly impacts efficacy of subsequent therapeutic strategies.
Materials and methods
Reagents and cell culture MGH121, MGH121 Res # 1 and PC9 cells were cultured in RPMI with 10% serum.
293FT cells were cultured in DMEM with 10% serum. PC9 cells were a gift from Pasi Janne, 293FT cells are from Invitrogen. MGH121 cells were generated from a pleural effusion of an erlotinib-resistant NSCLC patient on July 19, 2011 and were originally developed in ACL4 supplemented with 10% serum. Once completed the cell line was sequenced to confirm that it matched the patient effusion sample. Experiments involving the 293FT cells were completed within 6 months of purchasing from Invitrogen and did not undergo any further testing. PC9 cells were verified by STR analysis within 6 months to 1 year of experimentation. Gefitinib, Afatinib, WZ4002, CO-1686 and AZD-9291 were purchased from Selleck and re-suspended in DMSO. pEGFR antibody (pY1068) was from Abcam, total EGFR was from Santa Cruz Biotechnology. pERK (T202/Y204), total ERK, pS6 (S240/244), total S6, Actin, pAKT (T308) and total AKT were purchased from Cell Signaling Technologies. All antibodies were used at a concentration of 1:1000.
Generating in vitro resistant cell line MGH121 was derived from a pleural effusion of an erlotinib-resistant patient. The procedure for establishing this line has been described previously (15, 30, 41) . To generate resistance in this model, MGH121 parental cells were grown in increasing doses of WZ4002 starting at 10nM and increasing to 30, 100, 300, and 1000nM incrementally once the cells began to grow through the given dose.
Generating lentiviral constructs, lentivirus and stable expression cell lines Lentiviral constructs and lentivirus were generated using the ViraPower Lentiviral 
Results
Cell lines derived from biopsies of cancers that have become resistant to targeted therapies have been a valuable tool for studying acquired resistance to targeted therapies (29, 30) . In addition, cultivating resistance to targeted therapies in vitro has yielded clinically validated resistance mechanisms (10, 14, (31) (32) (33) (34) . To study acquired resistance to third generation EGFR TKIs, we took advantage of a cell line model that was derived from a biopsy of a resistant EGFR mutant (Exon 19 del) tumor that had developed T790M in the clinic after 7 months on erlotinib. This cell line, MGH121, was resistant to the first generation EGFR TKI gefitinib, consistent with the presence of the T790M resistance mutation, but was highly sensitive to the third generation TKI WZ4002 ( Figure 1A ). To model acquired resistance to third generation inhibitors in these cells, we cultured them in increasing doses of WZ4002, starting at 10nM and raising the concentration incrementally until the cells were growing in 1μM. This common approach for generating resistance in vitro has proven to consistently produce clinically relevant resistance mechanisms (10, 29) . The resulting resistant model, MGH121 Res # 1, was highly resistant to WZ4002 ( Figure 1A , B), and in addition, WZ4002 treatment failed to suppress EGFR phosphorylation and downstream signaling in these cells ( Figure 1C ). We hypothesized In this system, EGFR Exon 19 del/T790M phosphorylation was effectively inhibited by second and third generation TKIs, while phosphorylation of EGFR Exon 19 Del/T790M/C797S was not suppressed by any of the inhibitors tested ( Figure 2C ). To determine if the C797S mutation alone was sufficient to promote resistance to second and third generation TKIs in an EGFR mutant cell line, we stably expressed the EGFR Exon 19 Del/T790M/C797S in MGH121 parental cells. Neither afatinib nor WZ4002 were able to block EGFR phosphorylation or the downstream signaling in these cells ( Figure 2D) . Accordingly, the growth of these cells was resistant to all generations of EGFR TKIs ( Figure 2E ). Together, these data demonstrate that the C797S mutation is sufficient to promote resistance to second and third generation EGFR inhibitors by preventing suppression of the target.
We next wanted to identify whether the C797S mutation occurred in cis (on the same Figure 3B, lanes 1-4) . Conversely, EGFR with the Exon 19 del/C797S double mutant was inhibited by gefitinib and afatinib, but not WZ4002 (Fig 3B, lanes 5-8) . Thus, a C797S mutant, even in the absence of T790M, would clearly lead to resistance to a third generation TKI. This scenario might develop when EGFR mutant cancers are treated with third generation inhibitors in the first-line setting, and importantly, such cancers might be sensitive to Figure 3B, lanes 9 -13) . Finally, EGFR in the triple mutant (cis scenario) was resistant to all three generations of TKI as well as the combination of gefitinib and WZ4002 ( Figure 3B, lanes 14-18) . Of note, the second generation inhibitor, afatinib, suppressed EGFR when C797S and T790M were in trans. However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window, and thus the combination of a first and third generation TKI holds more promise.
We also modeled both the cis and trans configurations in the parental MGH121 cells by stably expressing either the triple mutant to recapitulate the cis scenario or the Exon 19 del/C797S for the trans situation (MGH121 parental cells carry an endogenous Exon 19 del/T790M allele). We observed results consistent with those from the previous overexpression experiment: The trans setting induced resistance to third generation TKI, but the combination of gefitinib and WZ4002 inhibited EGFR signaling ( Figure 3C ) and cell growth ( Figure 3D ). However, this combination was not effective when all the mutations were in cis.
These experiments demonstrate an important difference in drug response if the T790M and C797S mutations occur on the same or on different alleles, a result that has clinical implications.
To date, the majority of clinical trials of third generation EGFR TKIs have been conducted in the setting of erlotinib-resistant disease, but clinical trials testing these therapies in TKI naïve patients are currently ongoing (NCT02296125, NCT02186301). The finding that the C797S mutation in the absence of T790M is sufficient to cause resistance to third generation TKIs but retains sensitivity to gefitinib, raises the intriguing possibility that patients with acquired resistance to third generation TKI in the first line setting may subsequently respond to first or second generation TKIs in the second line setting. To test this hypothesis, we stably expressed EGFR with Exon 19 del/C797S in a TKI-naïve cell line, PC9, which is sensitive to all classes of EGFR inhibitors. PC9 Exon 19 Del/C797S cells were indeed resistant to WZ4002, but sensitive to gefitinib and afatinib (Figure 4 A, B) . By comparison, PC9 triple mutant cells were resistant to all EGFR inhibitors that were tested. This result supports the notion that patients that are treated with third generation TKI as their first EGFR inhibitor and acquire resistance driven by C797S may subsequently respond to first generation TKI. Of note, the concentration of afatinib required to suppress the growth of cells expressing the Exon 19 Del/C797S construct was markedly higher than the PC9 parental cells (Figure 4B ), suggesting that the C797S mutation leads to reduced potency of this drug. It remains to be determined whether the dose of afatinib necessary to inhibit mutant EGFR with a C797S mutation alone is achievable in patients given the aforementioned narrow therapeutic window.
Discussion
The efficacy of tyrosine kinase inhibitors has been limited by acquisition of resistance mutations that prevent inhibition of the target. For patients treated with the first generation EGFR TKIs gefitinib and erlotinib, the T790M resistance mutation has been observed in over half of resistant biopsies (12, 14) . In this paradigm and others, next generation TKIs have been developed to suppress oncogenic kinases that harbor resistance mutations. For T790M-positive EGFR mutant NSCLCs, third generation EGFR TKIs have been particularly effective and are poised to be approved by the FDA in this setting. In this study, we cultivated resistance to a third generation EGFR TKI in a T790M-positive cell line established from an erlotinibresistant biopsy. In these resistant cells, we report that another mutation to EGFR, C797S, prevents EGFR inhibition and promotes resistance to third generation EGFR TKIs. The initial study characterizing WZ4002 revealed that the covalent interaction between EGFR and the inhibitor is mediated by this cysteine residue and is necessary for the activity of third generation inhibitors in an in vitro kinase assay, and thus mutation of this amino acid is an excellent candidate for a resistance mutation (21) . To our knowledge our data serve as the first evidence that C797S can develop in an EGFR mutant cancer model treated chronically with a third generation EGFR TKI.
Our results suggest that treatment history and genetic background may have important therapeutic implications for cancers that have acquired a C797S mutation ( Figure 5 erlotinib has previously shown to be capable of suppressing EGFR with a mutation at C797 (36). This finding may also impact the current debate regarding whether it is better to give a third generation inhibitor in the first line or resistance setting. Importantly, these results suggest that combining first and third generation TKIs in the first line setting may be particularly powerful since neither a T790M nor a C797S mutation alone would be sufficient to drive resistance to this combination. PKC inhibitors such as midostaurin (PKC412) have recently been shown to non-covalently inhibit EGFR with T790M and thus may be able to suppress mutant EGFR with T790M and C797S in cis (37) . However, these drugs are limited by their lack of specificity and thus the potential for therapeutic window in this setting is uncertain.
The covalent interaction with C797 has also been demonstrated to be important to the activity of the pan-HER inhibitor CI-1033 (38, 39) and exogenous expression of a C797A mutant can confer resistance to another second generation inhibitor, HKI-272 (36). Our data reveal that at a concentration of 1μM, afatinib can inhibit mutant EGFR with C797S in the absence of T790M. Importantly, however, expression of mutant EGFR with C797S in PC9 cells results in a significant increase in the IC 50 of afatinib compared to parental PC9 cells. Of note, a similar reduction in activity of second generation inhibitors towards EGFR is caused by T790M (36, 40).
This decreased activity of second generation TKIs toward mutant EGFR with T790M diminishes the therapeutic window in these cancers resulting in the lack of clinical efficacy. It is likely that the same will be true for resistant EGFR mutant cancers harboring C797S.
Third generation EGFR inhibitors are proving to be effective treatments for erlotinibresistant cancers with T790M mutations and will soon become clinically available. Our results indicate that mutation of the C797 residue may be a mechanism by which these cancers 
progress on this class of drugs. Sequencing biopsy samples from patients whose tumors have progressed on third generation TKIs and determining if the C797S mutation is in cis or trans with T790M should be a priority going forward. Designing a treatment strategy that can suppress triple mutant EGFR may soon be needed. Figure 5 Research. 
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